Lupin shares continue to rise, trading at a new 52-week high of Rs 2,376 after a 15% return over two weeks. The Nifty Pharma ...

Indian pharma giant Lupin's shares surged more than 2 per cent to touch the all time high level after the company declared ...

Nilesh Gupta, Managing Director of Lupin, emphasised that this acquisition aligns with the company’s commitment to expanding ...

Global pharma major Lupin Limited announced today the acquisition of Huminsulin® in India from Eli Lilly and Company to ...

JSW Energy Ltd. shares are gaining attention after Motilal Oswal named it as their top pick in the power utility sector for ...

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

The drug is indicated for the treatment of HIV-1 infection and for pre-exposure prophylaxis to reduce the risk of HIV-1 ...

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood ...

Mumbai: Global pharma major Lupin Limited has announced the acquisition of Huminsulin in India from Eli Lilly and Company to ...

In this edition of Traders' Diary, the Zee Business research team shares exclusive research on 20 stocks that investors and ...

Emkay Global Financial is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2750 in its research report dated December 30, 2024.

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and ...